Skip to main content

Advertisement

Log in

Lost in translation: assessing the nomenclature change for diabetic kidney disease in Japan

  • Review Article
  • Published:
Diabetology International Aims and scope Submit manuscript

Abstract

Recently in Japan, the term "tonyobyo sei jinzobyo", the Japanese translation of "diabetic kidney disease", has been increasingly used in place of the term "tonyobyo sei jinsho", the Japanese translation of "diabetic nephropathy". Many international diabetes and nephrology guidelines have defined diabetic kidney disease as a condition caused by diabetes, typically presenting with albuminuria, similar to or identical to current and historical definitions for diabetic nephropathy. However, recent guidelines from the Japanese Society of Nephrology propose a broader disease concept for the term diabetic kidney disease, including patients without albuminuria. A rationale for proposing a broader disease concept for diabetic kidney disease may have come from changes in the kidney phenotype of patients with diabetes observed in recent years. Epidemiological studies have shown that an increasing proportion of patients with diabetes have reduced kidney function, while the prevalence of those with albuminuria appears to have decreased. However, these studies also suggested that the more advanced age of patients presenting with diabetes and increased use of renin-angiotensin system blockers may have contributed to this change in disease phenotype. We believe the principal rationale for the nomenclature change from diabetic nephropathy to diabetic kidney disease was to create a more easily understood, lay-language term for English speakers, rather than to create a term to encompass a broader population of diabetes with chronic kidney disease (CKD). Further discussion and international consensus are needed for the definition of diabetic kidney disease, to avoid ambiguity or possible confusion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Japanese Society of Nephrology. Evidence-based CKD Clinical Practice Guidelines 2018, Tokyo: Tokyo-igakusha; 2018

  2. The 64th Annual Meeting of the Japanese Society of Nephrology. http://jsn64.umin.jp/

  3. The 64th Annual Meeting of the Japan Diabetes Society. https://site.convention.co.jp/64jds/

  4. The American Diabetes Association 81st Scientific Sessions. https://ada.scientificposters.com/epsSearchADA.cfm

  5. Kidney Week 2021 of the American Society of Nephrology. https://www.asn-online.org/education/kidneyweek/2021/program-annual.aspx?day=Thursday

  6. Friedman EA. Diabetic nephropathy: strategies in prevention and management. Kidney Int. 1982;21:780–91.

    Article  CAS  PubMed  Google Scholar 

  7. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease with emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983;32(Suppl. 2):64–78.

    Article  PubMed  Google Scholar 

  8. Mogensen CE. Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int. 1987;31:673–89.

    Article  CAS  PubMed  Google Scholar 

  9. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2012;2013(3):1–150.

    Google Scholar 

  10. Haneda M, Utsunomiya K, Koya D, et al. A new classification of diabetic nephropathy 2014: a report from joint committee on diabetic nephropathy. Diabetol Int. 2014;5:207–11.

    Article  Google Scholar 

  11. Zins EI. Diabetic nephropathy. Am J Med Sci. 1949;218:408–18.

    Article  CAS  PubMed  Google Scholar 

  12. Wilson JL, Root HF, Marble A. Diabetic nephropathy; a clinical syndrome. N Engl J Med. 1951;245:513–7.

    Article  CAS  PubMed  Google Scholar 

  13. Goetz FC, Kjellstrand CM. The treatment of diabetic kidney disease. Diabetologia. 1979;17:267–81.

    Article  CAS  PubMed  Google Scholar 

  14. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med. 1984;310:356–60.

    Article  CAS  PubMed  Google Scholar 

  15. Mogensen CE, Schmitz A, Christensen CK. Comparative renal pathophysiology relevant to IDDM and NIDDM patients. Diabetes Metab Rev. 1988;5:453–83.

    Article  Google Scholar 

  16. KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49 (2):S1-S182

  17. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis. 2014;64:510–33.

    Article  PubMed  Google Scholar 

  18. Diabetes Canada Clinical Practice Guidelines Expert Committee, McFarlane P, Cherney D, et al. Chronic kidney disease in diabetes. Can J Diabetes. 2018; 42(1): S201-S209

  19. Liew A, Bavanandan S, Prasad N, et al. Asian Pacific society of nephrology clinical practice guideline on diabetic kidney disease. Nephrology. 2020;25(Suppl. 2):S12–45.

    Article  Google Scholar 

  20. Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol. 2007;27:195–207.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Cohen Tervaert TW, Mooyaart AL, Amann K, et al. Pathological classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21:556–63.

    Article  Google Scholar 

  22. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2020;98(4S):S1-S115

  23. Hur KY, Moon MK, Park JS, et al. 2021 Clinical practice guidelines for diabetes mellitus of the Korean diabetes association. Diabetes Metab J. 2021;45:461–81.

    Article  PubMed  PubMed Central  Google Scholar 

  24. National Institute for Health and Care Excellence (NICE). Chronic kidney disease: assessment and management: 2021. https://www.nice.org.uk/guidance/ng203/resources/chronic-kidney-disease-assessment-and-management-pdf-66143713055173

  25. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(Suppl. 1):S1–266.

    Google Scholar 

  26. Levey AS, Eckardt K-U, Dorman NM, et al. Nomenclature for kidney function and disease: report of a kidney disease: improving global outcomes (KDIGO) consensus conference. Kidney Int. 2020;97:1117–29.

    Article  PubMed  Google Scholar 

  27. Anders H-J, Huber TB, Isermann B, et al. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol. 2018;14:361–77.

    Article  CAS  PubMed  Google Scholar 

  28. Alicic RZ, Johnson EJ, Tuttle KR. Diabetic kidney disease. In: Himmelfarb J, Ikizler TA, editors. Chronic kidney disease, dialysis, and transplantation. 4th ed. Philadelphia: Elsevier; 2019. p. 42–61.

    Chapter  Google Scholar 

  29. Fornoni A, Nelson RG, Najafian B, Groop PH. Epidemiology of diabetic kidney disease. In: Yu ASL, Chertow GM, Luyckx V, Marsden PA, Skorecki K, Taal MW, editors. Brenner and rector’s the kidney. 11th ed. Elsevier; 2019. p. 1327–79.

    Google Scholar 

  30. Persson F, Rossing P. Diagnosis of diabetic kidney disease: state of the art and future perspective. Kidney Int Suppl. 2018;8:2–7.

    Article  Google Scholar 

  31. Yokoyama H, Araki S, Kawai K, et al. The prognosis of patients with type 2 diabetes and nonalbuminuric diabetic kidney disease is not always poor: implication of the effects of coexisting macrovascular complications (JDDM 54). Diabetes Care. 2020;43:1102–10.

    Article  CAS  PubMed  Google Scholar 

  32. Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. JAMA. 2016;316:602–10.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Tanaka N, Yamamoto Y, Yokoyama Y, et al. Temporal trends in the prevalence of albuminuria and reduced eGFR in Japanese patients with type 2 diabetes. Diabetol Int. 2019;10:279–87.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Kume S, Araki SI, Ugi S, et al. Secular changes in clinical manifestations of kidney disease among Japanese adults with type 2 diabetes from 1996 to 2014. J Diabetes Investig. 2019;10:1032–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Shiraishi N, Kitamura K, Kohda Y, et al. Prevalence and risk factor analysis of nephrosclerosis and ischemic nephropathy in the Japanese general population. Clin Exp Nephrol. 2014;18:461–8.

    Article  CAS  PubMed  Google Scholar 

  36. Glassock RJ, Delanaye P, Rule AD. Should the definition of CKD be changed to include age-adapted GFR criteria? YES Kidney Int. 2020;97:34–7.

    Article  PubMed  Google Scholar 

  37. Levey A, Inker LA, Coresh J. “Should the definition of CKD be changed to include age-adapted GFR criteria?” Con: the evaluation and management of CKD, not the definition, should be age-adapted. Kidney Int. 2020;97:37–40.

    Article  PubMed  Google Scholar 

  38. Rule AD, Amer H, Cornell LD, et al. The association between age and nephrosclerosis on renal biopsy among healthy adults. Ann Intern Med. 2010;152:561–7.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Masakane I, Nakai S, Ogata S, et al. An overview of regular dialysis treatment in Japan (As of 31 December 2013). Ther Apher Dial. 2015;19:540–74.

    Article  CAS  PubMed  Google Scholar 

  40. Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2019 Annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2020;75(suppl 1):6–7.

    Article  Google Scholar 

  41. Abe M, Okada K, Maruyama N, et al. Comparison of clinical trajectories before initiation of renal replacement therapy between diabetic nephropathy and nephrosclerosis on the KDIGO Guidelines Heat Map. J Diabetes Res 2016;5374746

  42. Anderson S, Rennke H, Brenner B. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest. 1986;77:1993–2000.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Araki S, Haneda M, Sugimoto T, et al. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes. 2005;54:2983–1987.

    Article  CAS  PubMed  Google Scholar 

  44. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–306.

    Article  CAS  PubMed  Google Scholar 

  45. Koye DN, Magliano DJ, Reid CM, et al. Risk of progression of nonalbuminuric CKD to end-stage kidney disease in people with diabetes: the CRIC (Chronic Renal Insufficiency Cohort) study. Am J Kidney Dis. 2018;72:653–66.

    Article  PubMed  Google Scholar 

  46. Yoshida Y, Kashiwabara K, Hirakawa Y, et al. Conditions, pathogenesis, and progression of diabetic kidney disease and early decliner in Japan. BMJ Open Diab Res Care. 2020;8: e000902.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Yamanouchi M, Furuichi K, Hoshino J, et al. Nonproteinuric versus proteinuric phenotypes in diabetic kidney disease: a propensity score-matched analysis of a nationwide, biopsy-based cohort study. Diabetes Care. 2019;42:891–902.

    Article  CAS  PubMed  Google Scholar 

  48. Yamamoto Y, Hanai K, Mori T, et al. Kidney outcomes and all-cause mortality in people with type 2 diabetes exhibiting non-albuminuric kidney insufficiency. Diabetologia. 2022;65:234–45.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tetsuya Babazono.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Babazono, T., Moriya, T. Lost in translation: assessing the nomenclature change for diabetic kidney disease in Japan. Diabetol Int 14, 319–326 (2023). https://doi.org/10.1007/s13340-023-00639-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13340-023-00639-9

Keywords

Navigation